[1] Rinella M E, Lazarus J V, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. Hepatology, 2023, 78(6): 1966-1986.
[2] Loomba R, Wong V W. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease[J]. Aliment Pharmacol Ther, 2024, 59(2): 150-156.
[3] Chalasani N, Younossi Z, Lavine J E, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67(1): 328-357.
[4] Wong V W, Chan W K, Chitturi S, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease Guidelines 2017-Part 1: definition, risk factors and assessment[J]. J Gastroenterol Hepatol, 2018, 33(1): 70-85.
[5] Chen M J, Chen Y, Lin J Q, et al. Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease[J]. Front Nutr, 2025, 11:1421386.
[6] Hassani Zadeh S, Mansoori A, Hosseinzadeh M. Relationship between dietary patterns and non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2021, 36(6): 1470-1478.
[7] Vancells Lujan P, Viñas Esmel E, Sacanella Meseguer E. Overview of non-alcoholic fatty liver disease (NAFLD) and the role of sugary food consumption and other dietary components in its development[J]. Nutrients, 2021, 13(5): 1442.
[8] He J, Wang Y, Weng F. Fast food consumption and risk of non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Front Public Health, 2025, 13:1600826.
[9] Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: evidence and plausible mechanisms[J]. Liver Int, 2017, 37(7): 936-949.
[10] Riazi K, Raman M, Taylor L, et al. Dietary patterns and components in nonalcoholic fatty liver disease (NAFLD): what key messages can health care providers offer?[J]. Nutrients, 2019, 11(12): 2878.
[11] Bjermo H, Iggman D, Kullberg J, et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial[J]. Am J Clin Nutr, 2012, 95(5): 1003-1012.
[12] Moore J B, Gunn P J, Fielding B A. The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease[J]. Nutrients, 2014, 6(12): 5679-5703.
[13] Xia Y, Wu Q, Dai H, et al. Associations of nutritional, lifestyle, and metabolic factors with non-alcoholic fatty liver disease: an umbrella review with more than 380 000 participants[J]. Front Nutr, 2021, 8:642509.
[14] Asgari-Taee F, Zerafati-Shoae N, Dehghani M, et al. Association of sugar sweetened beverages consumption with non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Eur J Nutr, 2019, 58(5): 1759-1769.
[15] Zhang X, Ruan J, He Y, et al. Dietary inflammatory index and the risks of non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Front Nutr, 2024, 11:1388557.
[16] Chen J, Zhou H, Jin H, et al. Role of inflammatory factors in mediating the effect of lipids on nonalcoholic fatty liver disease: a two-step, multivariable mendelian randomization study[J]. Nutrients, 2022, 14(20): 4434.
[17] Harrison S A, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis[J]. Am J Gastroenterol, 2003, 98(11): 2485-2490.
[18] Valibeygi A, Davoodi A, Dehghan A, et al. Dietary inflammatory index (DII) is correlated with the incidence of non-alcoholic fatty liver disease (NAFLD): fasa PERSIAN cohort study[J]. BMC Nutr,2023,9:84.
[19] Doustmohammadian A, Clark C C T, Maadi M, et al. Favorable association between mediterranean diet (MeD) and DASH with NAFLD among Iranian adults of the amol cohort study (AmolCS)[J]. Sci Rep,2022,12(1): 2131.
[20] Ebadi M, Ip S, Bhanji R A, et al. Effect of coffee consumption on non-alcoholic fatty liver disease incidence, prevalence and risk of significant liver fibrosis: systematic review with meta-analysis of observational studies[J]. Nutrients, 2021, 13(9): 3042.
[21] Sewter R, Heaney S, Patterson A. Coffee consumption and the progression of NAFLD: a systematic review[J]. Nutrients, 2021, 13(7): 2381.
[22] Coelho M, Patarrāo R S, Sousa-Lima I, et al. Increased intake of both caffeine and non-caffeine coffee components is associated with reduced NAFLD severity in subjects with type 2 diabetes[J]. Nutrients, 2022, 15(1): 4.
[23] Hsu S J, Lee F Y, Wang S S, et al. Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats[J]. Hepatology, 2015, 61(5): 1672-1684.
[24] Ma Q, Ye J, Shao C, et al. Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials[J]. Ther Adv Endocrinol Metab, 2022, 13:20420188221122426.
[25] Petersen A M W, Pedersen B K. The anti-inflammatory effect of exercise[J]. Journal of applied physiology, 2005, 98(4): 1154-1162.
[26] Słomko J, Zalewska M, Niemiro W, et al. Evidence-based aerobic exercise training in metabolic-associated fatty liver disease: systematic review with meta-analysis[J]. J Clin Med, 2021, 10(8): 1659.
[27] Babu A F, Csader S, Lok J, et al. Positive effects of exercise intervention without weight loss and dietary changes in NAFLD-related clinical parameters: a systematic review and meta-analysis[J]. Nutrients, 2021, 13(9): 3135.
[28] Yang H J, Hong Y P, Yoon T Y, et al. Independent and synergistic associations of aerobic physical activity and resistance exercise with nonalcoholic fatty liver disease[J]. Gut Liver, 2023, 17(4): 600-609.
[29] Whitsett M, VanWagner L B. Physical activity as a treatment of non-alcoholic fatty liver disease: a systematic review[J]. World journal of hepatology, 2015, 7(16): 2041.
[30] Hallsworth K, Adams L A. Lifestyle modification in NAFLD/NASH: facts and figures[J]. JHEP Rep, 2019, 1(6): 468-479.
[31] Lara-Romero C, Romero-Gómez M. Treatment options and continuity of care in metabolic-associated fatty liver disease: a multidisciplinary approach[J]. Eur Cardiol, 2024, 19:e06.
[32] Keating S E, Sabag A, Hallsworth K, et al. Exercise in the management of metabolic-associated fatty liver disease (MAFLD) in adults: a position statement from Exercise and Sport Science Australia[J]. Sports Med, 2023, 53(12): 2347-2371.
[33] Yang J, Zhang K, Xi Z, et al. Short sleep duration and the risk of nonalcoholic fatty liver disease/metabolic associated fatty liver disease: a systematic review and meta-analysis[J]. Sleep Breath, 2023, 27(5): 1985-1996.
[34] Zhang F, Xue Y, Li W. Exploring the impact of sleep duration and sleep disorders on metabolic dysfunction-associated steatotic liver disease in older adults[J]. BMC Geriatr, 2025,25(1): 61.
[35] Umbro I, Fabiani V, Fabiani M, et al. Association between non-alcoholic fatty liver disease and obstructive sleep apnea[J]. World J Gastroenterol, 2020, 26(20): 2669-2681.
[36] Zong G, Mao W, Wen M, et al. Association of sleep patterns and disorders with metabolic dysfunction-associated steatotic liver disease and liver fibrosis in contemporary American adults[J]. Ann Hepatol, 2024, 30(2): 101583.
[37] Xiao J, Lim L K E, Ng C H, et al. Is fatty liver associated with depression? A meta-analysis and systematic review on the prevalence, risk factors, and outcomes of depression and non-alcoholic fatty liver disease[J]. Front Med (Lausanne), 2021, 8:691696.
[38] Shea S, Lionis C, Kite C, et al. Non-alcoholic fatty liver disease (NAFLD) and potential links to depression, anxiety, and chronic stress[J]. Biomedicines, 2021, 9(11): 1697.
[39] Zhang S, Ma C, Wang X, et al. Impact of chronic psychological stress on nonalcoholic fatty liver disease[J]. Int J Clin Exp Med, 2019, 12: 7991-7998.
[40] Hänsel A, Hong S, Cámara R J, von Känel R. Inflammation as a psychophysiological biomarker in chronic psychosocial stress[J]. Neurosci Biobehav Rev,2010,35(1): 115-121.
[41] European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol,2016,64(6): 1388-1402.
[42] Lomonaco R, Sunny N E, Bril F, et al. Nonalcoholic fatty liver disease: current issues and novel treatment approaches[J]. Drugs,2013,73(1): 1-14.
[43] Kenneally S, Sier J H, Moore J B. Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review[J]. BMJ Open Gastroenterol, 2017, 4(1): e000139. |
